Strategies to discover unexpected targets for drugs active at G protein-coupled receptors

John Allen, Bryan L. Roth

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling molecules comprising approximately 2% of the human genome; this receptor family remains a central focus in basic pharmacology studies and drug discovery efforts. Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacology-that is, drugs with activity at more than one receptor target for which they were designed. These off-target drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clinical efficacy. Here we review physical screening and cheminformatic approaches that define drug activity at the GPCR receptorome. In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as offtargets underlying drug side effects. Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.

Original languageEnglish (US)
Pages (from-to)117-144
Number of pages28
JournalAnnual Review of Pharmacology and Toxicology
Volume51
DOIs
StatePublished - Feb 10 2011
Externally publishedYes

Fingerprint

G-Protein-Coupled Receptors
Pharmaceutical Preparations
Polypharmacology
Drug Receptors
Human Genome
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Screening
Pharmacology
Ligands
Genes
Molecules

Keywords

  • drug side effects
  • high-throughput screening
  • polypharmacology
  • receptorome
  • similarity ensemble approach
  • valvulopathy

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. / Allen, John; Roth, Bryan L.

In: Annual Review of Pharmacology and Toxicology, Vol. 51, 10.02.2011, p. 117-144.

Research output: Contribution to journalArticle

@article{cf886a4e52bb48cfa1776e792e549a19,
title = "Strategies to discover unexpected targets for drugs active at G protein-coupled receptors",
abstract = "G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling molecules comprising approximately 2{\%} of the human genome; this receptor family remains a central focus in basic pharmacology studies and drug discovery efforts. Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacology-that is, drugs with activity at more than one receptor target for which they were designed. These off-target drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clinical efficacy. Here we review physical screening and cheminformatic approaches that define drug activity at the GPCR receptorome. In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as offtargets underlying drug side effects. Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.",
keywords = "drug side effects, high-throughput screening, polypharmacology, receptorome, similarity ensemble approach, valvulopathy",
author = "John Allen and Roth, {Bryan L.}",
year = "2011",
month = "2",
day = "10",
doi = "10.1146/annurev-pharmtox-010510-100553",
language = "English (US)",
volume = "51",
pages = "117--144",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0362-1642",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Strategies to discover unexpected targets for drugs active at G protein-coupled receptors

AU - Allen, John

AU - Roth, Bryan L.

PY - 2011/2/10

Y1 - 2011/2/10

N2 - G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling molecules comprising approximately 2% of the human genome; this receptor family remains a central focus in basic pharmacology studies and drug discovery efforts. Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacology-that is, drugs with activity at more than one receptor target for which they were designed. These off-target drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clinical efficacy. Here we review physical screening and cheminformatic approaches that define drug activity at the GPCR receptorome. In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as offtargets underlying drug side effects. Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.

AB - G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling molecules comprising approximately 2% of the human genome; this receptor family remains a central focus in basic pharmacology studies and drug discovery efforts. Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacology-that is, drugs with activity at more than one receptor target for which they were designed. These off-target drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clinical efficacy. Here we review physical screening and cheminformatic approaches that define drug activity at the GPCR receptorome. In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as offtargets underlying drug side effects. Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.

KW - drug side effects

KW - high-throughput screening

KW - polypharmacology

KW - receptorome

KW - similarity ensemble approach

KW - valvulopathy

UR - http://www.scopus.com/inward/record.url?scp=79951512210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951512210&partnerID=8YFLogxK

U2 - 10.1146/annurev-pharmtox-010510-100553

DO - 10.1146/annurev-pharmtox-010510-100553

M3 - Article

C2 - 20868273

AN - SCOPUS:79951512210

VL - 51

SP - 117

EP - 144

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0362-1642

ER -